In rheumatology, the clearance of adalimumab, an anti-tumor necrosis factor-alpha (TNF-α) mAb used to treat adults with rheumatoid arthritis, is reduced by methotrexate, presumably through reducing the patient’s ability to make anti-drug antibodies (ADAs) against adalimumab21. The gene discussed is TNF; the disease is rheumatoid arthritis.